Behind the FDA Curtain: WarRoom/DailyClout Pfizer Reports
Newsletter (Digital)
Actions
Media Outlet details
| Scope | International |
|---|---|
| Language | N/A |
| Country | N/A |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesSafety Issues from CVXGA1 Sprayable COVID Vaccine Trial Results
A new sprayable COVID vaccine known as CVXGA1 has entered clinical testing with the goal of offering needle-free immunization against COVID-19. While early results show some immune activation and tolerability, the sprayable COVID vaccine has also prompted a wave of concerns over potential safety risks, particularly regarding viral shedding and the design of the initial study. CVXGA1 is delivered intranasally using a viral vector derived from parainfluenza virus type 5 (PIV5).